Table 2.
Pathogen | Antibiotic | Susceptibility estimates (Posterior median; 80% credible interval) |
---|---|---|
Acinetobacter spp. | Carbapenems | 0.54 (0.10, 0.93) |
Escherichia coli | Aminopenicillins | 0.16 (0.04, 0.47) |
Escherichia coli | Gentamicin | 0.47 (0.17, 0.80) |
Escherichia coli | Third-generation cephalosporins | 0.36 (0.11, 0.72) |
Escherichia coli | Carbapenems | 0.94 (0.78, 0.99) |
Haemophilus influenzae | Aminopenicillins | 0.46 (008, 0.86) |
Haemophilus influenzae | Gentamicin | 0.95 (0.68, 0.99) |
Haemophilus influenzae | Third-generation cephalosporins | 0.95 (0.66, 0.99) |
Haemophilus influenzae | Carbapenems | 1.00 (0.95, 1.00) |
Klebsiella spp. | Gentamicin | 0.49 (0.12, 0.87) |
Klebsiella spp. | Third-generation cephalosporins | 0.23 (0.03, 0.73) |
Klebsiella spp. | Carbapenems | 0.89 (0.51, 0.99) |
Neisseria meningitidis | Aminopenicillins | 0.34 (0.07, 0.75) |
Neisseria meningitidis | Third-generation cephalosporins | 0.98 (0.90, 1.00) |
Neisseria meningitidis | Carbapenems | 0.94 (0.59, 1.00) |
Pseudomonas spp. | Gentamicin | 0.78 (0.41, 0.95) |
Pseudomonas spp. | Carbapenems | 0.79 (0.43, 0.95) |
Salmonella spp. | Aminopenicillins | 0.61 (0.08, 0.96) |
Salmonella spp. | Third-generation cephalosporins | 0.97 (0.68, 1.00) |
Salmonella spp. | Carbapenems | 0.99 (0.84, 1.00) |
Streptococcus agalactiae | Aminopenicillins | 0.99 (0.98, 1.00) |
Streptococcus agalactiae | Third-generation cephalosporins | 0.98 (0.95, 0.99) |
Streptococcus agalactiae | Carbapenems | 0.99 (0.93, 1.00) |
Streptococcus pneumoniae | Aminopenicillins | 0.92 (0.66, 0.99) |
Streptococcus pneumoniae | Third-generation cephalosporins | 0.87 (0.54, 0.98) |
Streptococcus pneumoniae | Carbapenems | 0.67 (0.26, 0.92) |
Staphylococcus aureus | Aminopenicillins | 0.34 (0.08, 0.77) |
Staphylococcus aureus | Gentamicin | 0.78 (0.39, 0.95) |
Staphylococcus aureus | Third-generation cephalosporins | 0.62 (0.20, 0.91) |
Staphylococcus aureus | Carbapenems | 0.87 (0.51, 0.98) |
Note: Third-generation cephalosporins includes ceftriaxone and cefotaxime.